Based out of Singapore, Gero develops new drugs for ageing and other complicated disorders using its proprietary developed artificial intelligence (AI) platform. Recently, the company has secured $2.2 million (€1.9 million) in Series A funding, bringing the total capital raised since Gero’s founding to over $7.5 million (€6.4 million).
Gero’s founder Peter Fedichev, said, “We are happy with the recognition and support from these strategic investors who themselves are acknowledged leaders in the fields of AI and biotechnology. This will help us attain the necessary knowledge at the junction of biological sciences and AI/ML technologies that is necessary for the radical acceleration of drug discovery battling the toughest medical challenges of the 21st century. We hope that the technology will soon lead to a meaningful healthspan extension and quality of life improvements ”